C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis

American Journal of Gastroenterology

Volumn 110, Issue 6, 2015, Pages 802-819

  Mosli, Mahmoud H ^a,b,c   Zou, Guangyong ^a,c   Garg, Sushil K ^d   Feagan, Sean G ^c   MacDonald, John K ^c   Chande, Nilesh ^a,e   Sandborn, William J ^c,f   Feagan, Brian G ^a,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF MINNESOTA   (United States)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; LACTOFERRIN;

AREA UNDER THE CURVE; CASE CONTROL STUDY; COHORT ANALYSIS; COLONOSCOPY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; FECES ANALYSIS; GOLD STANDARD; HUMAN; INTESTINE ENDOSCOPY; META ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLISHING; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; CHEMISTRY; COLITIS, ULCERATIVE; FECES; GASTROINTESTINAL ENDOSCOPY; METABOLISM;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; FECES; HUMANS; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; SENSITIVITY AND SPECIFICITY;

EID: 84930754958     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.120     Document Type: Review

References (79)

1. Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141: 1194-201.
2. Froslie KF, Jahnsen J, Moum BA et al. Mucosal healing in inflammatory bowel disease: Results from a norwegian population-based cohort. Gastroenterology 2007;133: 412-22.
3. Bouguen G, Levesque BG, Feagan BG et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. advance online publication, 10 September 2013; pii: S1542-3565(13)01301-3.
4. Lasson A, Kilander A, Stotzer PO. Diagnostic yield of colonoscopy based on symptoms. Scand J Gastroenterol 2008;43: 356-62.
5. Leddin DJ, Paterson WG, DaCosta LR et al. Indium-111-labeled autologous leukocyte imaging and fecal excretion. Comparison with conventional methods of assessment of inflammatory bowel disease. Dig Dis Sci 1987;32: 377-87.
6. Loft us EV Jr. Clinical perspectives in Crohn's disease. Objective measures of disease activity: alternatives to symptom indices. Rev Gastroenterol Disord 2007;7 Suppl 2: S8-S16.
7. Powell-Tuck J, Day DW, Buckell NA et al. Correlations between defi ned sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982;27: 533-7.
8. Regueiro M, Kip KE, Schraut W et al. Crohn's disease activity index does not correlate wiThendoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011;17: 118-26.
9. Siemons L, Ten Klooster PM, Vonkeman HE et al. How age and sex aff ect the erythrocyte sedimentation rate and c-reactive protein in early rheumatoid arthritis. BMC Musculoskelet Disord 2014;15: 368.
10. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: treat registry. Clin Gastroenterol Hepatol 2006;4: 621-30.
11. Cobb WS, Heniford BT, Sigmon LB et al. Colonoscopic perforations: incidence, management, and outcomes. Am Surg 2004;70: 750-7. discussion 57-8.
12. Sipponen T, Nuutinen H, Turunen U et al. Endoscopic evaluation of Crohn's disease activity: comparison of the cdeis and the ses-cd. Inflamm Bowel Dis 2010;16: 2131-6.
13. Travis SP, Schnell D, Krzeski P et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013;145: 987-95.
14. Tsilidis KK, Branchini C, Guallar E et al. C-reactive protein and colorectal cancer risk: A systematic review of prospective studies. Int J Cancer 2008;123: 1133-40.
15. Jones J, Loftus EV Jr., Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6: 1218-24.
16. Kathiresan S, Larson MG, Vasan RS et al. Contribution of clinical correlates and 13 c-reactive protein gene polymorphisms to interindividual variability in serum c-reactive protein level. Circulation 2006;113: 1415-23.
17. Suk Danik J, Chasman DI, Cannon CP et al. Influence of genetic variation in the c-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet 2006;70: 705-16.
18. Henderson P, Kennedy NA, Van Limbergen JE et al. Serum c-reactive protein and crp genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy. Inflamm Bowel Dis 2015;21: 596-605.
19. Roseth AG, Aadland E, Jahnsen J et al. Assessment of disease activity inulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58: 176-80.
20. Summerton CB, Longlands MG, Wiener K et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14: 841-5.
21. Walker TR, Land ML, Kartashov A et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44: 414-22.
22. Angriman I, Scarpa M, D'Inca R et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007;381: 63-8.
23. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34: 50-4.
24. Dhote R, Beades E, Le Dinh T et al. 999mtc-hmpao scan imaging in Crohn's disease, scintigraphie aux leucocytes marques par l'hmpao 99mtc au cours de la maladie de Crohn. Acta Gastro-Enterol Belg 1995;58: 353-63.
25. Saboury B, Salavati A, Brothers A et al. Fdg pet/ct in Crohn's disease: correlation of quantitative fdg pet/ct parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging 2014;41: 605-14.
26. Tibble J, Teahon K, Thjodleifsson B et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47: 506-13.
27. Sipponen T, Savilahti E, Karkkainen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-tnf-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14: 1392-8.
28. Langhorst J, Elsenbruch S, Koelzer J et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and pmn-elastase, crp, and clinical indices. Am J Gastroenterol 2008;103: 162-9.
29. Manz M, Burri E, Rothen C et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012;12: 5.
30. Kallel L, Ayadi I, Matri S et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010;22: 340-5.
31. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic metaanalysis. BMJ 2010;341: c3369.
32. Whiting PF, Rutjes AW, Westwood ME et al. Quadas-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155: 529-36.
33. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001;20: 2865-84.
34. Hamza TH, Reitsma JB, Stijnen T. Meta-analysis of diagnostic studies: a comparison of random intercept, normal-normal, and binomial-normal bivariate summary roc approaches. Med Decis Making 2008;28: 639-49.
35. Reitsma JB, Glas AS, Rutjes AW et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58: 982-90.
36. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21: 1539-58.
37. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315: 629-34.
38. Berger C, Loitsch SM, Hartmann F et al. Comparative evaluation of fecal calprotectin and s100a12 as non-invasive markers for disease activity in inflammatory bowel disease. Gastroenterology 2011;1: S431.
39. Camacho-Escobedo JA, Tellez-Avila F, Barahona-Garrido J et al. Correlation between C-reactive protein and b2-microglobulin with histologic disease activity inulcerative colitis (UC). Gastroenterology 2008;134 (4 Suppl 1): A-214.
40. Canani RB, Terrin G, Rapacciuolo L et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008;40: 547-53.
41. Chung-Faye G, Hayee B, Maestranzi S et al. Fecal m2-pyruvate kinase (m2-pk): A novel marker of intestinal inflammation. Inflamm Bowel Dis 2007;13: 1374-8.
42. Chung-Faye G, Sandhu K, Logan RP et al. Fecal calproctectin is strongly predictive of clinical disease activity and histological severity in inflammatory bowel disease. Gastroenterology 2011;1: S421.
43. Chamouard P, Richert Z, Meyer N et al. Diagnostic value of c-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006;4: 882-7.
44. Halme L, von Smitten K, Stenman S et al. Concentrations of pancreatic secretory trypsin inhibitor (psti), acute phase proteins, and neopterin in Crohn's disease. Comparison with clinical disease activity and endoscopical findings. Scand J Clin Lab Invest 1993;53: 359-66.
45. Krzystek-Korpacka M, Neubauer K, Matusiewicz M. Clinical relevance of circulating midkine inulcerative colitis. Clin Chem and Lab Med 2009;47: 1085-90.
46. Morante AJL, Saezroyuela F, Delmoral LY et al. Serum of c-reactive protein in patients with ulcerative-colitis and Crohns-disease. Rev Esp Enferm Dig 1993;83: 5-9.
47. Vieira A, Fang CB, Rolim EG et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009;2: 221.
48. Bjorkesten CG, Nieminen U, Turunen U et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-tnftreated luminal Crohn's disease. Scand J Gastroenterol 2012;47: 528-37.
49. D'Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18: 2218-24.
50. Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis 2013;7: e641-e651.
51. Lobaton T, Rodriguez-Moranta F, Lopez A et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity inulcerative colitis. Inflamm Bowel Dis 2013;19: 1034-42.
52. Nancey S, Boschetti G, Moussata D et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2013;19: 1043-52.
53. Onal IK, Beyazit Y, Sener B et al. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis. Turk J Gastroenterol 2012;23: 509-14.
54. Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin more accurately refl ects endoscopic activity of ulcerative colitis than the lichtiger index, c-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013;19: 332-41.
55. Schoepfer AM, Beglinger C, Straumann A et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, c-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15: 1851-8.
56. Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (ses-cd) than crp, blood leukocytes, and the cdai. Am J Gastroenterol 2010;105: 162-9.
57. Yamamoto T, Shiraki M, Bamba T et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: a prospective pilot study. United European Gastroenterol J 2013;1: 368-74.
58. Inoue K, Aomatsu T, Yoden A et al. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2014;29: 1406-12.
59. D'Inca R, Pont E, Leo V et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22: 429-37.
60. Karoui S, Laz S, Serghini M et al. Correlation of c-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis. Dig Dis Sci 2011;56: 1801-5.
61. Masoodi I, Kochhar R, Dutta U et al. Fecal lactoferrin, myeloperoxidase and serum c-reactive are Effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J Gastroenterol Hepatol 2009;24: 1768-74.
62. Primas C, Fruhwald G, Angelberger S et al. Role of fecal calprotection in predicting ileocolonic endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2013;1: S619-S620.
63. Shastri Y, Povse N, Schrer O et al. Evaluation of a novel fecal markerfecal tumor pyruvate kinase type m2 (m2-pk) and its comparison with calprotectin in patients with inflammatory bowel disease: a prospective multicenter study. Gastroenterology 2008;134 (4 Suppl 1): A642.
64. Filik L, Dagli U, Ulker A. C-reactive protein and monitoring the activity of Crohn's disease. Adv Ther 2006;23: 655-62.
65. Lin JF, Chen JM, Zuo JH et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014;20: 1407-15.
66. Wander K, Brindle E, O'Connor KA. C-reactive protein across the menstrual cycle. Am J Phys Anthropol 2008;136: 138-46.
67. Wunder DM, Yared M, Bersinger NA et al. Serum leptin and c-reactive protein levels in the physiological spontaneous menstrual cycle in reproductive age women. Eur J Endocrinol 2006;155: 137-42.
68. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38: 905-10.
69. Oshitani N, Kitano A, Fukushima R et al. Predictive factors for the response of ulcerative colitis patients during the acute-phase treatment. Digestion 1990;46: 107-13.
70. Arias MT, Vande Casteele N, Vermeire S et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2015;13: 531-8.
71. Henriksen M, Jahnsen J, Lygren I et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008;57: 1518-23.
72. Kiss LS, Papp M, Lovasz BD et al. High-sensitivity c-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification? Inflamm Bowel Dis 2012;18: 1647-54.
73. Solem CA, Loftus EV Jr., Tremaine WJ et al. Correlation of c-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11: 707-12.
74. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10: 1079-87. quiz e85-6.
75. Primas C, Fruhwald G, Angelberger S et al. Role of fecal calprotection in predicting ileocolonic endoscopic recurrence in postoperative Crohn's disease. J Crohn's Colitis 2013;7: S162.
76. Silberer H, Kuppers B, Mickisch O et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005;51: 117-26.
77. Sandborn W, Panes J, Zhang H et al. Evaluation of the relationship between fecal calprotectin concentrations and clinical and endoscopic outcome measures in a phase 2 study of tofacitinib, an oral janus kinase inhibitor, inulcerative colitis. Gastroenterology 2013;144 (5 Suppl 1): S764.
78. D'Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132: 763-86.
79. Gecse KB, Brandse JF, van Wilpe S et al. Impact of disease location on fecal calprotectin levels in Crohn's disease. Scand J Gastroenterol 2015, 1-7.